ThinkSabio

$AMGN

$462.00▲ +3.1% YTD

17 SEC 13D/G filings tracked · Last updated Oct 28, 2026

Filing History
News
AMGN ▲ +3.1% - Amgen Inc.
CP $462.00▲ +3.1%Oct 28, 2026 · ThinkSabio Blog

$AMGN AMGN - AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS…

News
AMGN ▲ +1.6% - Amgen Inc.
CP $451.55▲ +1.6%Oct 27, 2026 · ThinkSabio Blog

$AMGN AMGN - AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND…

News
AMGN ▲ +1.7% - Amgen Inc.
CP $452.15▲ +1.7%Oct 27, 2026 · ThinkSabio Blog

$AMGN AMGN - AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026…

News
AMGN ▲ +1.1% - Amgen Inc.
CP $444.00▲ +1.1%Oct 26, 2026 · ThinkSabio Blog

$AMGN AMGN - AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS…

News
AMGN ▼ -1.8% - Amgen Inc.
CP $439.26▲ -1.8%Oct 24, 2026 · ThinkSabio Blog

$AMGN Conference data published Saturday show Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi cut the risk of death by 58% versus Imfinzi alone…

News
AMGN ▼ -1.8% - Amgen Inc.
CP $439.26▲ -1.8%Oct 24, 2026 · ThinkSabio Blog

$AMGN AMGN - IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCE…

News
AMGN ▼ -0.7% - Amgen Inc.
CP $444.02▲ -0.7%Oct 23, 2026 · ThinkSabio Blog

$AMGN — Oppenheimer raises PT to $480 from $450, maintains Outperform…

News
AMGN ▲ +3.4% - Amgen Inc.
CP $439.52▲ +3.4%Oct 20, 2026 · ThinkSabio Blog

$AMGN AMGN - AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026…

News
AMGN ▲ +0.9% - Amgen Inc.
CP $429.00▲ +0.9%Oct 20, 2026 · ThinkSabio Blog

$AMGN AMGN - TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS…

News
AMGN ▲ +0.9% - Amgen Inc.
CP $429.00▲ +0.9%Oct 20, 2026 · ThinkSabio Blog

$AMGN AMGEN: ASTHMA DRUG TEZSPIRE DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS; TEZSPIRE 210 MG & 420 MG ACHIEVE…

News
AMGN ▼ -0.4% - Amgen Inc.
CP $413.00▲ -0.4%Sep 28, 2026 · ThinkSabio Blog

$AMGN ONCY RVMD VSTM LLY - KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034…

News
AMGN ▲ +5.0% - Amgen Inc.
CP $412.95▲ +5.0%Sep 22, 2026 · ThinkSabio Blog

$AMGN AMGN - AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE…

News
AMGN ▲ +0.1% - Amgen Inc.
CP $377.71▲ +0.1%Sep 14, 2026 · ThinkSabio Blog

$AMGN AMGN - FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®…

News
AMGN ▼ -5.8% - Amgen Inc.
CP $411.91▲ -5.8%Sep 8, 2026 · ThinkSabio Blog

$AMGN AMGN - IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LU…

News
AMGN ▼ -7.1% - Amgen Inc.
CP $412.56▲ -7.1%Sep 4, 2026 · ThinkSabio Blog

$AMGN down ah…

News
AMGN ▲ +1.5% - Amgen Inc.
CP $444.50▲ +1.5%Sep 2, 2026 · ThinkSabio Blog

$AMGN AMGN - AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE…

News
AMGN ▼ -0.2% - Amgen Inc.
CP $431.50▲ -0.2%Aug 31, 2026 · ThinkSabio Blog

$AMGN REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE…